Home › Neuromyelitis Optica › NCT06398158

Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder

Clinical and Radiological Outcomes in People With Aquaporin-4 IgG Positive Neuromyelitis Optica Spectrum Disorder Treated With Ravulizumab

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Signed informed consent available prior to conduct of any study associated activities
2. Men and women \> 18 years of age
3. Aquaporin-4 IgG positive people with neuromyelitis optica spectrum disorder treated with commercially available ravulizumab in a manner consistent with the approved indication
4. Expanded Disability Status Scale score of \<7.0

Exclusion Criteria:

1. Individuals who are intolerant to MRI
2. Individuals previously exposed to eculizumab with treatment discontinuation due to lack of effective disease control (i.e., clinical relapse or demonstration of MRI advancement after 12 weeks of sustained treatment exposure)
3. Unresolved meningococcal disease
4. History of an active infection
5. Existing participation in neuromyelitis optical spectrum disorder interventional clinical studies
6. Pregnant or lactating women

About the study

This is an observational study to:

* evaluate the on-treatment clinical performance of ravulizumab in relation to the pre-treatment time period (time period prior to exposure), * enhance knowledge regarding conventional MRI outcomes in people with NMOSD treated with ravulizumab, * identify factors suggestive of subclinical disease progression through conventional MRI sequences, * determine if treatment with ravulizumab, impacts longitudinal 3D conformational MRI measures at the dorsal medulla and other regions of the CNS, and * identify biomarkers (e.g., serum neurofilament light chain (sNfL), conventional and novel MRI markers, etc.) related to disease activity.

What is being tested

• Ravulizumab (drug)

Sponsor: University of Texas Southwestern Medical Center · Participants: 35 · Started: Jul 10, 2024

Contact the study team

• Diem Tran, PhD · Phone: 214-645-9165
• Jose Santoyo · Phone: 214-645-1878

Official record on ClinicalTrials.gov — NCT06398158

Locations in the U.S.

Conditions

• Neuromyelitis Optica

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.